US | International
TOBA III Roundtable Discussion: Thomas Zeller, MD, Marianne Brodmann, MD (PI), and Michael Lichtenberg, MD
Tack Endovascular System: FDA Approved
TOBA II 12-month pivotal trial data, presented by Dr. William A. Gray
Post-PTA Dissection: Clinical Impact, Identification, and Repair
SFA Center: Repair of PTA Dissections in Lower Extremities with Tack Endovascular System®
Intact Vascular Receives Conditional FDA Approval for TOBA II Study of Tack System
Intact Vascular’s Tack Endovascular System Supported by 12-Month TOBA Data
TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for PAD patients.
Using the Tack Endovascular System to treat vessel dissection
Intact Vascular Announces Conditional FDA Approval for TOBA II Study and Enrolment of First Patients
Positive 12-Month Results of TOBA Clinical Trial
Philadelphia Business Journal: Medical-device developer raises $39M in venture capital deal
Start-Ups Across Health Care: Intact Vascular Inc. Optimizing balloon angioplasty for peripheral arterial disease
Intact Vascular, Inc.
1285 Drummers Lane, Suite 200
Wayne, PA 19087
Tack Endovascular System (6F) is FDA approved for use in the superficial femoral and proximal popliteal arteries (3.5-6.0mm RVD) for treatment of post-PTA dissections.
Tack Endovascular System (4F) is limited by federal (United States) law to investigational use. Not available for sale in the United States.
Tack Endovascular System is CE Mark authorized under EC Directive 93/42/EEC.
Adaptive Sizing™ is a trademark of Intact Vascular, Inc.
Tack Endovascular System® and Tack® are registered trademarks of Intact Vascular, Inc.